APO RESEARCH · REPORT
Biologics and Biosimilars
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
Product & engineering
Understand the product.
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
Selected research
Industry Research
Biologics and Biosimilars Industry Research Report 2026
Market perspective
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.
Read the full market overview
Report Scope
This report quantifies the global Biologics and Biosimilars market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biologics and Biosimilars Market by Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Biologics and Biosimilars Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Biologics and Biosimilars Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
Biologics and Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biologics and Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biologics and Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Others
Applications
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Others
Companies covered
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- United Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Biologics and Biosimilars Market Size (2021-2032)
- 2.2.2 Global Biologics and Biosimilars Sales (2021-2032)
- 2.2.3 Global Biologics and Biosimilars Market Average Price (2021-2032)
- 2.3 Biologics and Biosimilars by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Monoclonal Antibodies
- 2.3.3 Interferon
- 2.3.4 Erythropoietin
- 2.3.5 Insulin
- 2.3.6 Vaccines
- 2.3.7 Others
- 2.4 Biologics and Biosimilars by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Tumor
- 2.4.3 Diabetes
- 2.4.4 Cardiovascular
- 2.4.5 Hemophilia
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Biologics and Biosimilars Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Biologics and Biosimilars Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Biologics and Biosimilars Revenue of Manufacturers (2021-2026)
- 3.4 Global Biologics and Biosimilars Average Price by Manufacturers (2021-2026)
- 3.5 Global Biologics and Biosimilars Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Biologics and Biosimilars, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Biologics and Biosimilars, Product Type & Application
- 3.8 Global Manufacturers of Biologics and Biosimilars, Established Date
- 3.9 Global Biologics and Biosimilars Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Roche
- 4.1.1 Roche Company Information
- 4.1.2 Roche Business Overview
- 4.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Roche Biologics and Biosimilars Product Portfolio
- 4.1.5 Roche Recent Developments
- 4.2 Amgen
- 4.2.1 Amgen Company Information
- 4.2.2 Amgen Business Overview
- 4.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amgen Biologics and Biosimilars Product Portfolio
- 4.2.5 Amgen Recent Developments
- 4.3 AbbVie
- 4.3.1 AbbVie Company Information
- 4.3.2 AbbVie Business Overview
- 4.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AbbVie Biologics and Biosimilars Product Portfolio
- 4.3.5 AbbVie Recent Developments
- 4.4 Sanofi-Aventis
- 4.4.1 Sanofi-Aventis Company Information
- 4.4.2 Sanofi-Aventis Business Overview
- 4.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
- 4.4.5 Sanofi-Aventis Recent Developments
- 4.5 Johnson & Johnson
- 4.5.1 Johnson & Johnson Company Information
- 4.5.2 Johnson & Johnson Business Overview
- 4.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
- 4.5.5 Johnson & Johnson Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Biologics and Biosimilars Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Novo Nordisk
- 4.7.1 Novo Nordisk Company Information
- 4.7.2 Novo Nordisk Business Overview
- 4.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
- 4.7.5 Novo Nordisk Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 Novartis
- 4.9.1 Novartis Company Information
- 4.9.2 Novartis Business Overview
- 4.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novartis Biologics and Biosimilars Product Portfolio
- 4.9.5 Novartis Recent Developments
- 4.10 Merck
- 4.10.1 Merck Company Information
- 4.10.2 Merck Business Overview
- 4.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Merck Biologics and Biosimilars Product Portfolio
- 4.10.5 Merck Recent Developments
- 4.11 3sbio
- 4.11.1 3sbio Company Information
- 4.11.2 3sbio Business Overview
- 4.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 3sbio Biologics and Biosimilars Product Portfolio
- 4.11.5 3sbio Recent Developments
- 4.12 Changchun High Tech
- 4.12.1 Changchun High Tech Company Information
- 4.12.2 Changchun High Tech Business Overview
- 4.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
- 4.12.5 Changchun High Tech Recent Developments
- 4.13 CP Guojian
- 4.13.1 CP Guojian Company Information
- 4.13.2 CP Guojian Business Overview
- 4.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
- 4.13.5 CP Guojian Recent Developments
- 4.14 Biotech
- 4.14.1 Biotech Company Information
- 4.14.2 Biotech Business Overview
- 4.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Biotech Biologics and Biosimilars Product Portfolio
- 4.14.5 Biotech Recent Developments
- 4.15 Gelgen
- 4.15.1 Gelgen Company Information
- 4.15.2 Gelgen Business Overview
- 4.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Gelgen Biologics and Biosimilars Product Portfolio
- 4.15.5 Gelgen Recent Developments
- 4.16 Innovent
- 4.16.1 Innovent Company Information
- 4.16.2 Innovent Business Overview
- 4.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Innovent Biologics and Biosimilars Product Portfolio
- 4.16.5 Innovent Recent Developments
- 4.17 Dong Bao
- 4.17.1 Dong Bao Company Information
- 4.17.2 Dong Bao Business Overview
- 4.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
- 4.17.5 Dong Bao Recent Developments
- 4.18 Ganlee
- 4.18.1 Ganlee Company Information
- 4.18.2 Ganlee Business Overview
- 4.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Ganlee Biologics and Biosimilars Product Portfolio
- 4.18.5 Ganlee Recent Developments
- 4.19 United Laboratories
- 4.19.1 United Laboratories Company Information
- 4.19.2 United Laboratories Business Overview
- 4.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
- 4.19.5 United Laboratories Recent Developments
5 Global Biologics and Biosimilars Market Scenario by Region
- 5.1 Global Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Biologics and Biosimilars Sales by Region: 2021-2032
- 5.2.1 Global Biologics and Biosimilars Sales by Region: 2021-2026
- 5.2.2 Global Biologics and Biosimilars Sales by Region: 2027-2032
- 5.3 Global Biologics and Biosimilars Revenue by Region: 2021-2032
- 5.3.1 Global Biologics and Biosimilars Revenue by Region: 2021-2026
- 5.3.2 Global Biologics and Biosimilars Revenue by Region: 2027-2032
- 5.4 North America Biologics and Biosimilars Market Facts & Figures by Country
- 5.4.1 North America Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Biologics and Biosimilars Sales by Country (2021-2032)
- 5.4.3 North America Biologics and Biosimilars Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Biologics and Biosimilars Market Facts & Figures by Country
- 5.5.1 Europe Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Biologics and Biosimilars Sales by Country (2021-2032)
- 5.5.3 Europe Biologics and Biosimilars Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Biologics and Biosimilars Market Facts & Figures by Country
- 5.6.1 Asia Pacific Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Biologics and Biosimilars Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Biologics and Biosimilars Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Biologics and Biosimilars Market Facts & Figures by Country
- 5.7.1 South America Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Biologics and Biosimilars Sales by Country (2021-2032)
- 5.7.3 South America Biologics and Biosimilars Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Biologics and Biosimilars Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Biologics and Biosimilars Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Biologics and Biosimilars Sales by Type (2021-2032)
- 6.1.1 Global Biologics and Biosimilars Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Biologics and Biosimilars Sales Market Share by Type (2021-2032)
- 6.2 Global Biologics and Biosimilars Revenue by Type (2021-2032)
- 6.2.1 Global Biologics and Biosimilars Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Biologics and Biosimilars Revenue Market Share by Type (2021-2032)
- 6.3 Global Biologics and Biosimilars Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Biologics and Biosimilars Sales by Application (2021-2032)
- 7.1.1 Global Biologics and Biosimilars Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Biologics and Biosimilars Sales Market Share by Application (2021-2032)
- 7.2 Global Biologics and Biosimilars Revenue by Application (2021-2032)
- 7.2.1 Global Biologics and Biosimilars Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Biologics and Biosimilars Revenue Market Share by Application (2021-2032)
- 7.3 Global Biologics and Biosimilars Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Biologics and Biosimilars Value Chain Analysis
- 8.1.1 Biologics and Biosimilars Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Biologics and Biosimilars Production Mode & Process
- 8.2 Biologics and Biosimilars Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Biologics and Biosimilars Distributors
- 8.2.3 Biologics and Biosimilars Customers
9 Global Biologics and Biosimilars Analyzing Market Dynamics
- 9.1 Biologics and Biosimilars Industry Trends
- 9.2 Biologics and Biosimilars Industry Drivers
- 9.3 Biologics and Biosimilars Industry Opportunities and Challenges
- 9.4 Biologics and Biosimilars Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst